There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nurix Therapeutics (NRIX – Research Report) and Mainz Biomed B.V. (MYNZ – Research Report) with bullish...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Mainz Biomed...
Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%.
Mainz Biomed partners with Quest Diagnostics to commercialize a colorectal cancer screening test, enhancing early detection efforts.Quiver AI SummaryMainz Biomed N.V. has announced a partnership with Quest...
Mainz Biomed closed a follow-on offering, raising approximately $8 million through the sale of 1,367,521 units.Quiver AI SummaryMainz Biomed N.V. has successfully completed a follow-on offering of 1,367,521...
Mainz Biomed announces $8 million follow-on offering of 1,367,521 units, including shares and warrants, priced at $5.85 each.Quiver AI SummaryMainz Biomed N.V. has announced a follow-on offering of 1,367,521...
Mainz Biomed announces a 1-for-40 reverse stock split to meet Nasdaq listing standards, effective December 3, 2024.Quiver AI SummaryMainz Biomed N.V. has announced a 1-for-40 reverse stock split, effective...
Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today
Maintaining a healthy weight is important for general health, but growing evidence reveals obesity’s role in the development of chronic illnesses and even deadly cancers. Obesity is one of the most frequent...
One of the most stubborn, deadly cancers is pancreatic cancer. What if individualized mRNA vaccinations could support the immune system’s defense? One of the deadliest forms of cancer around, pancreatic...